Trial · NCT03822208
First in Human Study for Safety and Tolerability of AL003.
NCT03822208, Phase 1, Completed, Alector Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. First in Human Study for Safety and Tolerability of AL003. Trials, record NCT03822208. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03822208
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- First in Human Study for Safety and Tolerability of AL003.
- NCT number
- NCT03822208
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 54 participants, actual
- Lead sponsor
- Alector Inc.
- Conditions
- Healthy, Alzheimer Disease
- Interventions
- AL003, Saline Solution
- First posted
- 2019-01-30
- Last updated
- 2021-09-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of safety and tolerability of AL003 measured by number of subjects with adverse events and dose limiting adverse events (DLAE) | 141 days | Incidence of adverse events during the treatment and follow up periods through out the study. |
| Secondary | Pharmacokinetics (PK) of AL003 | 85 days | Serum and CSF concentration of AL003 at specific time points |
| Secondary | Maximum concentration (Cmax) for AL003 | 85 days | Evaluate Cmax for serum and CSF concentration of AL003 at specified time points |
| Secondary | Area under the curve concentration (AUC) for AL003 | 85 days | Evaluate AUC for serum and CSF concentration of AL003 at specified time points |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03822208
GET https://conductscience.org/api/trials/v1/NCT03822208/registered